Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Interest & Investment Income (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Interest & Investment Income for 13 consecutive years, with $9.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest & Investment Income rose 27.47% year-over-year to $9.7 million, compared with a TTM value of $39.4 million through Dec 2025, up 43.12%, and an annual FY2025 reading of $37.3 million, up 64.17% over the prior year.
  • Interest & Investment Income was $9.7 million for Q4 2025 at Arrowhead Pharmaceuticals, up from $9.1 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $11.0 million in Q2 2025 and bottomed at $1.1 million in Q1 2022.
  • Average Interest & Investment Income over 5 years is $4.7 million, with a median of $4.0 million recorded in 2023.
  • The sharpest move saw Interest & Investment Income crashed 49.47% in 2021, then skyrocketed 332.64% in 2023.
  • Year by year, Interest & Investment Income stood at $1.2 million in 2021, then surged by 132.01% to $2.7 million in 2022, then increased by 4.47% to $2.8 million in 2023, then skyrocketed by 171.31% to $7.6 million in 2024, then grew by 27.47% to $9.7 million in 2025.
  • Business Quant data shows Interest & Investment Income for ARWR at $9.7 million in Q4 2025, $9.1 million in Q3 2025, and $11.0 million in Q2 2025.